Effect of supervised resistance training on arm volume, quality of life and physical perfomance among women at high risk for breast cancer-related Lymphedema: A study protocol for a randomized controlled Trial (STRONG-B)
Date
2022-03Author
Ramírez-Parada, Karol
Lopez-Garzon, Maria
Sanchez-Rojel, Cesar
Petric-Guajardo, Militza
Alfaro-Barra, Margarita
Fernández-Verdejo, Rodrigo
Reyes-Ponce, Alvaro
Merino-Pereira, Gina
Cantarero-Villanueva, Irene
Materias
Breast cancer lymphedema
Breast neoplasms
Physical therapy specialty
Quality of life
Resistance training
Statistics
Share
Abstract
Objectives: To determine the preventive effects of supervised resistance training on arms
volume, quality of life, physical performance, and handgrip strength in Chilean women at
high risk for breast cancer-related lymphedema (BCRL) undergoing chemotherapy.
Design: Randomized control trial.
Participants: One hundred and six women at high risk for breast cancer-related
lymphedema aged 18 to 70 years.
Interventions: Participants will be randomized into two groups: [a] intervention, who will
receive 12 weeks of supervised resistance training (STRONG-B) during adjuvant
chemotherapy; and [b] control, who will receive education to promote lymphatic and
venous return, maintain range of motion, and promote physical activity.
Main Outcome Measures: The primary outcome will be arms volume measured with an
optoelectric device (perometer NT1000). Secondary outcomes will be quality of life,
handgrip strength, and physical performance. Primary and secondary outcomes will be
measured at baseline, just after the intervention, and 3 and 6 months after. Statistical analysis will be performed following intention-to-treat and per-protocol approaches. The
treatment effect will be calculated using linear mixed models.
Discussion: The STRONG-B will be a tailored supervised resistance training that
attempts to prevent or mitigate BCRL in a population that, due to both intrinsic and
extrinsic factors, will commonly suffer from BCRL.
Clinical Trial Registration: [https://clinicaltrials.gov/ct2/show/NCT04821609], identifier
NCT04821609.